Cipla shares slide 5% after temporary halt in key drug manufacturing

Cipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply is expected to resume in H1 FY27. The stock trades near oversold levels, with bearish technical indicators, amid investor concern over the limited availability of a top US product.